Urban Wealth Management LLC Sells 6,589 Shares of CVS Health Corporation $CVS

Urban Wealth Management LLC lowered its stake in CVS Health Corporation (NYSE:CVS) by 18.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,862 shares of the pharmacy operator’s stock after selling 6,589 shares during the period. CVS Health makes up approximately 2.1% of Urban Wealth Management LLC’s investment portfolio, making the stock its 11th biggest position. Urban Wealth Management LLC’s holdings in CVS Health were worth $2,073,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in CVS. TOWER TRUST & INVESTMENT Co boosted its holdings in shares of CVS Health by 0.8% in the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after purchasing an additional 132 shares during the period. CYBER HORNET ETFs LLC raised its holdings in CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after buying an additional 134 shares during the period. LS Investment Advisors LLC raised its holdings in CVS Health by 3.9% during the 4th quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock valued at $284,000 after buying an additional 135 shares during the period. Moss Adams Wealth Advisors LLC lifted its position in CVS Health by 4.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after buying an additional 135 shares during the last quarter. Finally, Northwestern Mutual Investment Management Company LLC boosted its stake in CVS Health by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock worth $3,219,000 after buying an additional 136 shares during the period. 80.66% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Barclays boosted their price objective on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. Wolfe Research dropped their price target on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Piper Sandler reiterated an “overweight” rating and set a $113.00 price target on shares of CVS Health in a report on Monday, June 1st. Bank of America increased their price objective on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Wall Street Zen raised shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Sunday, June 21st. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average target price of $101.28.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding its direct-to-consumer GLP-1 weight-loss program, which could support new growth and improve margins if demand continues. CVS expands direct-to-consumer GLP-1 weight-loss program
• Positive Sentiment: Analysts/valuation updates have nudged CVS’s implied fair value higher, reflecting improving views on GLP-1 engagement, margins, and earnings resilience. CVS Health (CVS) Stock Sees Modest Fair Value Lift As GLP 1 And Margins Help
• Positive Sentiment: CVS Health Foundation announced $2 million in combined grants to Hartford- and Rhode Island-area nonprofits, reinforcing community ties and its local health access message. CVS Health Foundation invests $1 million in Hartford nonprofits tackling community health needs
• Positive Sentiment: CVS won a whistleblower drug lawsuit, removing a potential legal overhang. CVS Health Beats Whistleblower’s Worthless Services Drug Suit

CVS Health Stock Performance

CVS stock opened at $104.50 on Friday. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $104.94. The firm has a market cap of $133.33 billion, a price-to-earnings ratio of 46.03, a PEG ratio of 1.00 and a beta of 0.62. The business’s fifty day simple moving average is $91.23 and its two-hundred day simple moving average is $82.24. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.